RecruitingNCT07039149

Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents

Dual Antiplatelet Agents Therapy in the Emergency Department for Acute Coronary Syndrome (The DATES Study).

Sponsor

Jordan Collaborating Cardiology Group

Enrollment

200 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

major bleeding Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Summary

This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with major adverse cardiovascular and cerebrovascular events (macce) and major bleeding. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

Jordan University Hospital

Amman, Jordan

Istishari Hospital

Amman, Jordan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07039149